|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Aging (NIA) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00104572 |
Purpose
The purpose of this study is to determine if an aromatase inhibitor (a drug that inhibits the conversion of testosterone to estrogen) is as effective as testosterone replacement in improving muscle mass, muscle strength, sexual function, memory, and bone health.
| Condition | Intervention | Phase |
|---|---|---|
|
Aging Hypogonadism Andropause |
Drug: Anastrozole Drug: Testosterone Gel Drug: Placebo tablet Drug: Placebo gel Dietary Supplement: Calcium Cardone 500mg with vitamin D 400 IU |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | The Effects of Aromatase Inhibition on Sex Steroids, Pituitary Hormones, Markers of Bone Turnover, Muscle Strength and Cognition on Older Men |
| Estimated Enrollment: | 75 |
| Study Start Date: | August 2004 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
25 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months
|
Drug: Testosterone Gel
5.0 - 7.5 mg gel daily for 12 months
Other Name: Androgel
Drug: Placebo tablet
Daily for 12 months
Dietary Supplement: Calcium Cardone 500mg with vitamin D 400 IU
1 tablet three times a day
Other Name: OsCal
|
|
Experimental: 2
25 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months
|
Drug: Anastrozole
1 mg tablet daily for 12 months
Other Name: Arimidex
Dietary Supplement: Calcium Cardone 500mg with vitamin D 400 IU
1 tablet three times a day
Other Name: OsCal
|
|
Placebo Comparator: 3
25 participants will receive a placebo tablet and placebo gel daily for 12 months
|
Drug: Placebo tablet
Daily for 12 months
Drug: Placebo gel
Daily for 12 months
Dietary Supplement: Calcium Cardone 500mg with vitamin D 400 IU
1 tablet three times a day
Other Name: OsCal
|
Approximately 20% of men over the age of 70 have low testosterone levels. In some studies, testosterone replacement has resulted in improvement in bone mass, muscle strength, quality of life and memory function. In the body, testosterone is converted into estrogen. Hence, it is unclear whether these beneficial effects are due to testosterone or estrogen. Research has shown that inhibition of estrogen production in men results in an increase in testosterone levels.
In this study, patients will be assigned to one of three groups: one group will receive testosterone gel and a placebo tablet, one group will receive a 1mg Anastrozole tablet and a placebo gel, and one group will receive a placebo tablet and placebo gel. Each group will receive a daily dose of calcium with vitamin D. The study requires 6 visits over a 12-month period for testing and evaluation. Two of the 6 visits will require an overnight stay in the hospital so that an intravenous (IV) line can be placed in the arm to allow samples to be drawn throughout the night. Testing will include a cardiac stress test, a glucose tolerance test, bone and muscle tests, evaluation of memory function, etc. For the safety of the prostate, we will perform a prostate ultrasound at the start and end of the study and we will monitor urinary symptoms, prostate specific antigen (PSA) levels and the prostate exam throughout the study.
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Denise Melvin | 410-350-3924 | melvinde@grc.nia.nih.gov |
| United States, Maryland | |
| National Institute on Aging (NIA), Harbor Hospital | Recruiting |
| Baltimore, Maryland, United States, 21225 | |
| Contact: Denise Melvin, Study Coordinator 410-350-3924 or 800-225-2572 ext 3924 melvinde@grc.nia.nih.gov | |
| Contact: NIA Recruiter 410-350-3941 NIAStudiesRecruitment@mail.nih.gov | |
| Principal Investigator: | Josephine M Egan, MD | Chief, Diabetes Section, LCI/NIA/NIH |
More Information
| Responsible Party: | Josephine Egan, MD, Principal Investigator, National Institute on Aging |
| ClinicalTrials.gov Identifier: | NCT00104572 History of Changes |
| Other Study ID Numbers: | AG0018 |
| Study First Received: | March 1, 2005 |
| Last Updated: | October 15, 2010 |
| Health Authority: | United States: Federal Government |
|
Low testosterone level glucose tolerance estrogen bone density |
quality of life memory function sarcopenia |
|
Hypogonadism Gonadal Disorders Endocrine System Diseases Testosterone Testosterone enanthate Testosterone undecanoate Testosterone 17 beta-cypionate Methyltestosterone Anastrozole Vitamin D Vitamins Androgens Hormones |
Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Anabolic Agents Bone Density Conservation Agents Micronutrients Growth Substances Aromatase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |